Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California. Show more

Location: 3940 Trust Way, Hayward, CA, 94545, United States | Website: https://benitec.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

361.7M

52 Wk Range

$9.10 - $17.15

Previous Close

$13.78

Open

$13.83

Volume

481,169

Day Range

$13.63 - $14.36

Enterprise Value

263.3M

Cash

97.74M

Avg Qtr Burn

-5.897M

Insider Ownership

3.12%

Institutional Own.

91.06%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.